Skip to main content

Table 5 Summary of clinical trials of capecitabine and irinotecan in the first-line setting

From: Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients

Study Year Treatment Number of patients ORR (%) PFS (months) OS (months) Grade 3/4 diarrhea (%)
Bajetta, et al [9] 2004 CAPIRI vs XELIRI 140 CAPIRI 44 CAPIRI 7.6 CAPIRI 17
XELIRI 47 XELIRI 8.3 XELIRI 36
Borner, et al [8] 2005 CAPIRI vs XELIRI 75 CAPIRI 34 CAPIRI 6.9 CAPIRI 17.4 CAPIRI 34
XELIRI 35 XELIRI 9.2 XELIRI 24.7 XELIRI 19
Cartwright, et al [10] 2005 XELIRI 49 45 6.2 13.4 20
Patt, et al [11] 2007 XELIRI 52 46 TTP 7.1 15.6 20
Rea, et al [24] 2005 XELIRI 57 42 TTP 8.3 9
Garcia-Alfonso, et al [15] 2009 XELIRI (every 2 weeks) 53 40 TTP 8.4 19.3 15.9
Choi, et al [16] 2008 XELIRI (every 2 weeks) 43 51 TTP 10.1 15.4 8.1
  1. CAPIRI: capecitabine and irinotecan; ORR: objective response rate; OS: overall survival; PFS: progression-free survival; TTP: time to progression; XELIRI: irinotecan and capecitabine.
\